Evidence map›Paper›PMID 36431337›Full record

ArticleJournal of clinical medicine2022

Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study.

Shuqin Xie, Yuan Yu, Yi Liu, Siliang Zhang, Shiyi Yuan, Kui Fan, Bin Tang, Qin Zhou, Yuqing Sun, Rui Liu and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Shuqin XieDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Yuan YuDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Yi LiuDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Siliang ZhangDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Shiyi YuanDepartment of Nephrology, Yongchuan People's Hospital of Chongqing, Chongqing 402160, China.
Kui FanDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Bin TangDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Qin ZhouDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Yuqing SunDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Rui LiuDepartment of Nephrology, Dianjiang People's Hospital of Chongqing, Chongqing 408300, China.
Dan CaoThe Department of Nephrology, The Fifth Hospital of Chongqing, Chongqing 400062, China.
Yong ChenDepartment of Nephrology and Hematopathology, Second Affiliated Hospital at Fengjie, Chongqing Medical University, Chongqing 404600, China.
Yelei WangDepartment of Nephrology, People's Hospital of Pengshui County, Chongqing 409600, China.
Guangjun LiuDepartment of Nephrology, People's Hospital of Shizhu County, Chongqing 409100, China.
Huan MaDepartment of Nephrology, Dianjiang People's Hospital of Chongqing, Chongqing 408300, China.
Chenghui TaoDepartment of Nephrology, Fengdu People's Hospital, Chongqing 408200, China.
Li ZengDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Ling ZhongDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Dalian Medical University · CNSecond Affiliated Hospital of Chongqing Medical University · CNChongqing Medical University · CNFirst People's Hospital of Chongqing · CN

Funding

National Natural Science Foundation of China 82200829Senior Medical Talents Program of Chongqing for Young and Middle-aged 2021the Chongqing Science and Technology Committee cstc2018jscx-msybX0120
6 · The paper itself

Abstract

purposeTo compare the safety and efficacy of percutaneous paricalcitol injection with intravenously administered paricalcitol in treating parathyroid hyperplasia in patients with secondary hyperparathyroidism (SHPT).

methodsThis study was approved by the Ethics Committee of our institution. We retrospectively collected data on patients who received percutaneous paricalcitol injection (24 patients) and intravenously administered paricalcitol (22 patients) based on their intact parathyroid hormone (iPTH) level. Serum iPTH, calcium, phosphorus, and the volume of the parathyroid gland were measured at several indicated time points after treatment, and adverse events associated with the two treatments were evaluated.

resultsAfter 6 months of follow-up, we found that patients from the percutaneous injection group had significantly decreased levels of iPTH (from 1887.81 ± 726.81 pg/mL to 631.06 ± 393.06 pg/mL), phosphate (from 1.94 ± 0.36 mmol/L to 1.71 ± 0.34 mmol/L), and volume of the parathyroid gland (from 0.87 ± 0.50 cm

conclusionsPercutaneous paricalcitol injection is a selective treatment for SHPT in ESRD.

Indexed as

end stage renal disease (ESRD)intravenously paricalcitol (IP)local paricalcitol injection (LPI)secondary hyperparathyroidism (SHPT)

Identifiers

PMID36431337
PMCPMC9693598
OpenAlexW4309737625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.